Medical and Pharma Insider’s Post

Our President & CEO, Woody Bryan, PhD, recently spoke with Ellen Capon of Drug Target Review about our lead candidate for #EosinophilicEsophagitis and other #AllergicDiseases. Read the article to learn how our investigational therapy is tackling the root cause of allergic conditions by shifting the immune system from a pro-inflammatory state to a homeostatic state and impacting both the regulatory and effector arms of the immune system: https://bit.ly/3MDXP2X

Medication knowledge - DUPIXENT Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as eczema (atopic dermatitis), asthma and nasal polyps which result in chronic sinusitis. It is also used for the treatment of eosinophilic esophagitis and prurigo nodularis. Dupixent must be stored at a temperature between 2 and 8°C. You can store up to 4 Dupixent pre-filled pens in LifeinaBox, the world's smallest fridge, available on www.lifeina.com. #dupixent #sanofi #transportmedication

03 Types of Adverse Drug Reactions - Bleeding - Cardiovascular - Infections - Hypoglycemia - Allergic Reactions - Renal Complications Drug Types associated with ADRs? - Anticoagulants - Antibiotics - Diabetes agents - Blood clotting meds - Cardiovascular meds - Anti-inflammatory NSAIDs - Diuretics How to get started with UGenome's Personalized Medication Service? 1. Order $399 test kit 2. Swab to collect sample 3. Return sample free of charge 4. Receive PGx report in 3-4 weeks https://lnkd.in/gZhay7Rn Sources - Riedl & Casillas (2003). Adverse drug reactions: types and treatment options. American family physician. - Marsh (2023). Adverse Drug Reactions. Merck Manual Adverse Drug Reaction (Code C142385). National Cancer Institute. #ugenome, #pharmacogenetics, #genomicmedicine, #personalizedmedicine, #precisionmedicine, #health, #medicationmanagement

🚨 **Hopes Dashed for Monkeypox Drug** 🧬 Early results from a clinical trial have shown that the antiviral drug tecovirimat is no more effective than a placebo against the clade I strain of the monkeypox virus, which is spreading in Africa. This disappointing outcome has raised concerns about the effectiveness of current treatments for this particular strain, underscoring the need for continued research and development of more effective therapies. #Monkeypox #Tecovirimat #ClinicalTrials #Healthcare #InfectiousDiseases

🔬 Exciting News: FDA permits marketing of first point-of-care Hepatitis C RNA test! The U.S. Food and Drug Administration's recent approval of the first point-of-care Hepatitis C RNA test marks a significant advancement in diagnostic technology. This innovative test allows for rapid and accurate detection of Hepatitis C, enhancing patient care and treatment outcomes. Another step forward in healthcare innovation! 🌟 #FDAApproval #HepatitisC #MedicalInnovation #DiagnosticTechnology https://lnkd.in/gRXPqckP

Celltrion gains a 'first mover' advantage in Europe and Korea with the XOLAIR biosimilar 'OMLYCLO' - Korea's first XOLAIR biosimilar approved for allergic asthma and chronic idiopathic urticaria - Acceleration towards a KRW 5 trillion global market: market share and sales expected to increase due to first-mover advantage - Rapid expansion of new treatment areas: autoimmune diseases, anti-cancer, and allergic asthma https://lnkd.in/eZ4bni7P

Phase 3 Trial Highlights Efficacy of Dupilumab for EoE in Children Aged 1 to 11: Dupilumab may improve disease severity in children with eosinophilic esophagitis (EoE). #finance #pharmacy #lifesciences

Today, the U.S. Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the following treatment indications, which are also currently approved for Soliris: the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis; and the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. https://lnkd.in/gTcnB5Pg

Velocity sites and investigators have now supported research for 12 products that received U.S. FDA approval in 2024! This year’s groundbreaking approvals include: • Ebglyss (lebrikizumab-lbkz) by Eli Lilly and Company, a new treatment for moderate to severe atopic dermatitis (eczema). • mRESVIA by Moderna, a vaccine to protect seniors from lower respiratory tract infections caused by RSV. • Livdelzi (seladelpar) by Gilead Sciences, a second-line treatment for primary biliary cholangitis (PBC). • Capavaxive by Merck, a pneumococcal vaccine for preventing invasive pneumococcal disease in adults. • Ohtuvayre (ensifentrine) by Verona Pharma, the first inhaled treatment for the maintenance of COPD, allowing for broad use in COPD patients. Thank you to our dedicated teams, partners, and patients for making this impact possible. This is why we do what we do, and the journey continues! #ClinicalTrials #ClinicalResearch #FDAApproval #Innovation #Healthcare

Island Pharmaceuticals’ Scientific Advisory Board member, Professor Stephen J. Thomas, MD from Upstate Global Health Institute (of Upstate Medical University) discusses the complexities of #dengue fever, and explains why effective #vaccine development has proven so difficult in this short video clip. This explanation underpins the potential opportunity for Island Pharmaceuticals with our dengue fever preventative and treatment candidate, ISLA-101.    Watch the full video interview here ➡️ https://shorturl.at/ANAb4